Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model

Award Number: R01CA290719
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model - Project Summary Adoptively transferred natural killer (ATNK) cells have an established and likely growing role for the treatment of hematologic malignancies, particularly in the context of hematopoietic stem cell transplants. However, despite a growing understanding of the critical role these cells play in the immune response against solid tumors, multiple trials have failed to translate these findings to the clinic. One major reason for this disconnect may relate to the immune suppressive tumor microenvironment (TME). In our published studies, we have demonstrated that antibody B10G5 targeting the MHC I chain related molecule (MIC) that is broadly expressed by human solid tumors can significantly modulate TME, re-invigorating CD8 T cell activity, reviving, activating, and sustaining circulating NK cells. Our anti-MIC antibody serves as a partial agonist antibody that captures the immune suppressive sMIC secreted by tumors, to form an agonist for the NKG2D receptor to upregulate the key signaling molecule CD3z to enable NK cells better function through ADCC and NCRs. We also reported that B10G5 can increase the high affinity enable IL-2Ra expression on NK cells, and sensitize them to low doses of IL-2 in the TME. However, development and optimization of combination therapy with this antibody is challenging with current pre-clinical models as there are numerous differences between murine and human NK cells. Most importantly for our purposes is that the MIC gene is not present in mice. Although our group developed a MIC expressing murine models to overcome this, its power is limited in addressing questions related to NK cell combination therapies. To better model adoptive NK therapy, we have been studying canine soft tissue sarcomas (STS) in client-owned (pet) dogs as predictive models for human undifferentiated pleomorphic sarcoma (UPS) which is the human STS subtype most analogous to canine STS. We developed reliable protocols for generating canine NK cell products at therapeutic doses, from various sources, using procedures appropriate for the veterinary clinic and mirroring those used for humans. The Specific Aims are: Aim 1: To determine the safe and effective dose of B10G5 in activating endogenous NK cells infiltrating canine STS and reshaping the TME. We hypothesize that B10G5 will activate infiltrating NK cells, and possible CD8T cells, reshaping the STS tumor immune microenvironment for tumor control. Aim 2: To optimize the adoptive transfer of NK cells for STS. We hypothesize LD chemotherapy will promote persistence and proliferation of both allogeneic and autologous NK product. Aim 3: To determine if B10G5 will act synergistically with ATNK. We hypothesize that B10G5 will enable adoptively transferred NK cells to effectively eliminate canine STS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $657,844 )
2026	2026	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Treatment Research	000	2	4/6/2026	NON-COMPETING CONTINUATION	$657,844
														Subtotal = $657,844

Issue Date FY: 2025 ( Subtotal = $672,844 )
2025	2025	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Treatment Research	000	1	3/7/2025	NEW	$672,844
														Subtotal = $672,844

Grand Total All Awards = $1,330,688

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model

Award Number: R01CA290719

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer